Oncology "Me-Too" Drugs Compared With Original Drugs in Randomized Clinical Trials.
作者信息
Olivier Timothée, Smith Calvin, Prasad Vinay, Mohyuddin Ghulam Rehman
机构信息
Department of Oncology, Geneva University Hospital, Geneva, Switzerland.
Frank H. Netter MD School of Medicine, Quinnipiac University, North Haven, Connecticut.
出版信息
JAMA Intern Med. 2025 Jul 14. doi: 10.1001/jamainternmed.2025.2892.
Abstract
摘要
相似文献
1
Oncology "Me-Too" Drugs Compared With Original Drugs in Randomized Clinical Trials.随机临床试验中肿瘤学“Me-Too”药物与原研药物的比较
JAMA Intern Med. 2025 Jul 14. doi: 10.1001/jamainternmed.2025.2892.
3
Randomised controlled trial to assess the impact of hospital-community pharmaceutical care on drug-related problems in oncology practice for at-risk outpatients treated with oral anticancer drugs-a French Society for Oncology Pharmacy (SFPO) study: DROP-SFPO study protocol.评估医院-社区药学服务对口服抗癌药物治疗的高危门诊肿瘤患者药物相关问题影响的随机对照试验——法国肿瘤药学协会（SFPO）研究：DROP-SFPO研究方案
BMJ Open. 2025 Jun 27;15(6):e094825. doi: 10.1136/bmjopen-2024-094825.
4
Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.拓扑替康、聚乙二醇化脂质体盐酸多柔比星和紫杉醇用于晚期卵巢癌二线或后续治疗：一项系统评价和经济学评估
Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. doi: 10.3310/hta10090.
5
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
6
Factors in Time to Full Approval or Withdrawal for Anticancer Medicines Granted Accelerated Approval by the FDA.美国食品药品监督管理局（FDA）加速批准的抗癌药物完全获批或撤回所需时间的影响因素。
JAMA Netw Open. 2025 Mar 3;8(3):e252026. doi: 10.1001/jamanetworkopen.2025.2026.
7
Association of Launch Price and Clinical Value With Reimbursement Decisions for Anticancer Drugs in China.抗癌药物上市价格与临床价值与中国药品报销决策的相关性研究
Int J Health Policy Manag. 2024;13:8150. doi: 10.34172/ijhpm.2024.8150. Epub 2024 Apr 22.
8
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.用于预防和治疗健康成人及儿童流感的神经氨酸酶抑制剂。
Cochrane Database Syst Rev. 2012 Jan 18;1:CD008965. doi: 10.1002/14651858.CD008965.pub3.
9
Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review.2005 - 2014年美国支持处方药补充适应症获批的疗效证据特征：系统评价
BMJ. 2015 Sep 23;351:h4679. doi: 10.1136/bmj.h4679.
10
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
本文引用的文献
1
Me-too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists.Me-too药物：历史、定义、实例及其与药品短缺和基本药物清单的相关性。
Br J Clin Pharmacol. 2020 Nov;86(11):2114-2122. doi: 10.1111/bcp.14327. Epub 2020 May 13.
2
Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.奥希替尼治疗未经治、-突变型晚期 NSCLC 的总生存期。
N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.
3
Competition and price among brand-name drugs in the same class: A systematic review of the evidence.同类别品牌药物之间的竞争与价格：证据的系统评价。
PLoS Med. 2019 Jul 30;16(7):e1002872. doi: 10.1371/journal.pmed.1002872. eCollection 2019 Jul.
4
Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration.分析美国食品和药物管理局批准的抗癌药物随机临床试验中的对照臂质量。
JAMA Oncol. 2019 Jun 1;5(6):887-892. doi: 10.1001/jamaoncol.2019.0167.
5
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
6
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.阿来替尼对比克唑替尼用于未经治疗的 ALK 阳性非小细胞肺癌。
N Engl J Med. 2017 Aug 31;377(9):829-838. doi: 10.1056/NEJMoa1704795. Epub 2017 Jun 6.
Zotero 插件